Life-saving new cancer drugs are being held back so the Government can save money, claims GlaxoSmithKline chief executive

Not an option: the drug Avastin, made by the firm Roche to treat breast cancer, was one of the drugs rejected by Nice and is therefore not available on the NHS

Sir Andrew accused governments of treating the pharmaceuticals industry as a ‘simple procurement business’ without understanding the wider implications of their decisions.

‘As governments have got more and more anxious about their debt positions and austerity agendas, what happened is quite predictable,’ he said.

‘If you are a minister and you need to cut costs, it is a lot easier to cut drug prices than it is to close a hospital or reduce the size of the Civil Service. I understand that.


http://www.dailymail.co.uk/
  • UK is delaying the approval of new treatments
  • Several new drugs have been blocked by Nice, says academic

    By DAILY MAIL REPORTER

The head of Britain’s biggest drugs company has accused the Government of systematically delaying the introduction of new cancer drugs in order to save money.

GlaxoSmithKline chief executive Sir Andrew Witty warned that ministers were making false economies as they tried to grapple with the deficit in the public finances.

In an interview with the BBC, he said that governments across Europe had already cut drug prices by 5 per cent a year – costing GSK around £300 million per annum.

Warning: Sir Andrew Witty, head of GSK, warns that government attempts to save money by delaying the introduction of new drugs is a false economyWarning: Sir Andrew Witty, head of GSK, warns that government attempts to save money by delaying the introduction of new drugs is a false economy

However, he said governments were now seeking to go further in an effort to achieve even bigger savings – and he highlighted Britain’s decision to delay new cancer treatments.

‘The bit I’m much more frightened about is that what’s now beginning to become clear is that, in addition to price reductions, governments are delaying the approval of innovative new drugs,’ he said.

‘So a second way they can save money, they think, is ‘Let’s just not buy the next round of innovation’.

‘Cancer in the UK is a good example where we’re seeing oncology drugs being systematically delayed from introduction and reimbursement. Leer más “Life-saving new cancer drugs are being held back so the Government can save money, claims GlaxoSmithKline chief executive”

MediaCom and Starcom split US$152m GSK media brief

By Staff Reporters
GLOBAL – GlaxoSmithKline has retained MediaCom to handle its US$95 million UK media planning and buying account, but the WPP agency has lost some European business to Starcom MediaVest Group.
MediaCom and Starcom split US$152m GSK media brief

GSK, which owns brands including Lucozade and Aquafresh, has appointed Starcom to duties previously held by MediaCom in Germany, Austria, Switzerland, Spain and Portugal.

The review did not include Central and Eastern Europe and Russia, held by Starcom, and the US, held by MediaCom.

News of the review broke in October last year, but at the time was denied by the client, who officially announced the international review just months later in April 2010, when it said it was to review the account in “selected key markets” around the world, including China.


GLOBAL – GlaxoSmithKline has retained MediaCom to handle its US$95 million UK media planning and buying account, but the WPP agency has lost some European business to Starcom MediaVest Group.

MediaCom and Starcom split US$152m GSK media brief

GSK, which owns brands including Lucozade and Aquafresh, has appointed Starcom to duties previously held by MediaCom in Germany, Austria, Switzerland, Spain and Portugal.

The review did not include Central and Eastern Europe and Russia, held by Starcom, and the US, held by MediaCom.

News of the review broke in October last year, but at the time was denied by the client, who officially announced the international review just months later in April 2010, when it said it was to review the account in “selected key markets” around the world, including China. Leer más “MediaCom and Starcom split US$152m GSK media brief”